SCHEMBL2935449

SCHEMBL2935449

Cc1ccc(C(=O)NC[C@H](NC(=O)c2cccc(-c3ccccc3)n2)C(=O)N[C@@H](CC(C)C)B(O)O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 13/20 0.67
PSMB1 P20618 5/20 0.67
PSMB2 P49721 5/20 0.67
PSMB8 P28062 4/20 0.67
PSMB9 P28065 4/20 0.67
PSMB10 P40306 4/20 0.67
ELANE P08246 2/20 0.67
CTSG P08311 2/20 0.67
CMA1 P23946 2/20 0.67
CYP3A4 P08684 1/20 0.67
CNR2 P34972 2/20 0.56
CLPP Q16740 2/20 0.50
LONP1 P36776 4/20 0.47
PSMB11 A5LHX3 3/20 0.47
PSMA7 O14818 3/20 0.47
PSMA1 P25786 3/20 0.47
PSMA2 P25787 3/20 0.47
PSMA3 P25788 3/20 0.47
PSMA4 P25789 3/20 0.47
PSMA5 P28066 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13079104 0.90 PSMB5 (0.59) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL2934069 0.88 PSMB5 (0.51) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL8259978 0.87 PSMB5 (0.59) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL2934112 0.86 PSMB5 (0.49) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL3152605 0.86 PSMB5 (0.49) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL3152611 0.86 PSMB5 (0.49) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL2926138 0.85 PSMB5 (0.67) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL8257202 0.85 PSMB5 (0.67) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL2931869 0.85 PSMB5 (0.53) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL2928006 0.84 PSMB5 (0.52) PSMB5PSMB1PSMB2PSMB8PSMB9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP claimed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
US-20090075936-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-03-19 US disclosed
US-20090075936-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-03-19 US disclosed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US disclosed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US disclosed
WO-2006086600-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075936-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 PSMB5 2/4885PSMB1 4/4885PSMB2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.